Nanodose Therapeutics is a biopharmaceutical company focused on developing safe and effective treatments to tackle chronic conditions,

​

Our portfolio of products and our proprietary formulation technology address significant unmet medical needs. Our portfolio consists of patent protected, late-stage, well-characterized molecules with clear regulatory paths to approval.

 

And upon approval, we expect to have 12 years of regulatory exclusivity in addition to our patent exclusivity.  Our pipeline products will compete in large markets that have significant unmet medical needs. 

​

Our programs include:

​

• NT-101 (NanoSLO) is our lead asset and is a recombinant protein that could be the first product approved for chronic Traumatic Brain Injury. We expect to have the efficacy and the safety necessary to make a remarkable impact on the quality of life for a majority of the patients suffering from this devastating condition.  

​

• NT-201 (NanoSLO plus an undisclosed compound) which is under development for another chronic and devastating condition – Alzheimer’s Disease - which affects close to 7 million people in the U.S.

​​

• NT-202 (NanoSLO plus another undisclosed compound) is another product in development that also takes aim at stroke - another chronic neurological condition. Stroke is not only the 5th leading cause of death in the U.S., but costs the healthcare system in excess of $56 billion each year.

​​

​​